Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Lusingu, John Pa ^a   Gesase, Samwel ^a   Msham, Salum ^a   Francis, Filbert ^a   Lemnge, Martha ^a   Seth, Misago ^a   Sembuche, Samwel ^a   Rutta, Acleus ^a   Minja, Daniel ^a   Segeja, Method D ^a   Bosomprah, Samuel ^b   Cousens, Simon ^b   Noor, Ramadhani ^c   Chilengi, Roma ^c   Druilhe, Pierre ^d  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c African Malaria Network Trust   (Tanzania)

^d INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 3 VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; ENGERIX-B; HEPATITIS B VACCINE; MSP3 PROTEIN, PLASMODIUM FALCIPARUM (181 276); MSP3 PROTEIN, PLASMODIUM FALCIPARUM (181-276); PARASITE ANTIGEN; PEPTIDE FRAGMENT; RECOMBINANT VACCINE;

ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; IRRITABILITY; MALARIA CONTROL; MALARIA FALCIPARUM; MONOCYTE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; TANZANIA; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; MOLECULAR GENETICS; SUBCUTANEOUS DRUG ADMINISTRATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTE ACTIVATION; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PLASMODIUM FALCIPARUM; TANZANIA; VACCINES, SYNTHETIC;

EID: 68949088772     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-163     Document Type: Article

References (21)

1. The global distribution of clinical episodes of Plasmodium falciparum malaria. RW Snow CA Guerra AM Noor HY Myint SI Hay, Nature 2005 434 214 217
2. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. JG Breman, Am J Trop Med Hyg 2001 64 1 11
3. A new global malaria eradication strategy. R Feachem O Sabot, Lancet 2008 371 1633 1635
4. Malaria vaccines: are we getting closer? JE Epstein B Giersing G Mullen V Moorthy TL Richie, Curr Opin Mol Ther 2007 9 12 24
5. A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. A Jafarshad MH Dziegiel R Lundquist LK Nielsen S Singh PL Druilhe, J Immunol 2007 178 3099 3106
6. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. H Bouharoun-Tayoun P Attanath A Sabchareon T Chongsuphajaisiddhi P Druilhe, J Exp Med 1990 172 1633 1641
7. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. C Oeuvray H Bouharoun-Tayoun H Gras-Masse E Bottius T Kaidoh M Aikawa MC Filgueira A Tartar P Druilhe, Blood 1994 84 1594 1602
8. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. SD Polley KK Tetteh JM Lloyd OJ Akpogheneta BM Greenwood KA Bojang DJ Conway, J Infect Dis 2007 195 279 287
9. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. S Soe M Theisen C Roussilhon KS Aye P Druilhe, Infect Immun 2004 72 247 252
10. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. C Roussilhon C Oeuvray C Muller-Graf A Tall C Rogier JF Trape M Theisen A Balde JL Perignon P Druilhe, PLoS Med 2007 4 e320
11. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. H Bouharoun-Tayoun C Oeuvray F Lunel P Druilhe, J Exp Med 1995 182 409 418
12. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. R Audran M Cachat F Lurati S Soe O Leroy G Corradin P Druilhe F Spertini, Infect Immun 2005 73 8017 8026
13. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. P Druilhe F Spertini D Soesoe G Corradin P Mejia S Singh R Audran A Bouzidi C Oeuvray C Roussilhon, PLoS Med 2005 2 e344
14. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. SB Sirima I Nebie A Ouedraogo AB Tiono AT onate A Gansane AI Derme A Diarra A Ouedraogo I Soulama, Vaccine 2007 25 2723 2732
15. Relationship between altitude and intensity of malaria transmission in the Usambara Mountains, Tanzania. R Bodker J Akida D Shayo W Kisinza HA Msangeni EM Pedersen SW Lindsay, J Med Entomol 2003 40 706 717
16. Altitude-dependent and -independent variations in Plasmodium falciparum prevalence in northeastern Tanzania. CJ Drakeley I Carneiro H Reyburn R Malima JP Lusingu J Cox TG Theander WM Nkya MM Lemnge EM Riley, J Infect Dis 2005 191 1589 1598
17. Levels of plasma immunoglobulin G with specificity against the cysteine-rich interdomain regions of a semiconserved Plasmodium falciparum erythrocyte membrane protein 1, VAR4, predict protection against malarial anemia and febrile episodes. JP Lusingu AT Jensen LS Vestergaard DT Minja MB Dalgaard S Gesase BP Mmbando AY Kitua MM Lemnge D Cavanagh, Infect Immun 2006 74 2867 2875
18. Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. H Reyburn R Mbatia C Drakeley J Bruce I Carneiro R Olomi J Cox WM Nkya M Lemnge BM Greenwood, JAMA. 2005 293 12 1461 1470
19. Human antibody subclass ELISA. P Druilhe H Bouharoun-Tayoun, Methods Mol Med 2002 72 457 459
20. Antibodies in falciparum malaria: what matters most, quantity or quality? H Bouharoun-Tayoun P Druilhe, Mem Inst Oswaldo Cruz 1992 87 Suppl 3 229 234
21. The economic and social burden of malaria. J Sachs P Malaney, Nature 2002 415 680 685